Genomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid Leukemia

Chinese Medical Journal
Bian-Hong WangLi Yu

Abstract

Intermediate-risk acute myeloid leukemia (IR-AML), which accounts for a substantial number of AML cases, is highly heterogeneous. We systematically summarize the latest research progress on the significance of gene mutations for prognostic stratification of IR-AML. We conducted a systemic search from the PubMed database up to October, 2014 using various search terms and their combinations including IR-AML, gene mutations, mutational analysis, prognosis, risk stratification, next generation sequencing (NGS). Clinical or basic research articles on NGS and the prognosis of gene mutations in IR-AML were included. The advent of the era of whole-genome sequencing has led to the discovery of an increasing number of molecular genetics aberrations that involved in leukemogenesis, and some of them have been used for prognostic risk stratification. Several studies have consistently identified that some gene mutations have prognostic relevance, however, there are still many controversies for some genes because of lacking sufficient evidence. In addition, tumor cells harbor hundreds of mutated genes and multiple mutations often coexist, therefore, single mutational analysis is not sufficient to make accurate prognostic predictions. The comp...Continue Reading

References

Sep 27, 2000·Human Molecular Genetics·T H Bestor
Aug 3, 2004·Nature Medicine·Bert Vogelstein, Kenneth W Kinzler
Jan 22, 2005·The New England Journal of Medicine·Brunangelo FaliniUNKNOWN GIMEMA Acute Leukemia Working Party
Oct 16, 2007·Oncogene·T Pabst, B U Mueller
Dec 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frederik DammJürgen Krauter
Dec 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Annika DufourKarsten Spiekermann
May 5, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claire L GreenRosemary E Gale
Nov 12, 2010·The New England Journal of Medicine·Timothy J LeyRichard K Wilson
Nov 30, 2010·Cell Stem Cell·Yoshikane KikushigeKoichi Akashi
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciHartmut Döhner
Feb 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Klaus H MetzelerClara D Bloomfield
Feb 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Verena I GaidzikKonstanze Döhner
Mar 9, 2011·Proceedings of the National Academy of Sciences of the United States of America·Max JanRavindra Majeti
Jun 15, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Felicitas TholMichael Heuser
Nov 26, 2011·Leukemia·S WeissmannA Kohlmann
Dec 14, 2011·Hematology·Hartmut Döhner, Verena I Gaidzik
Feb 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Mar 21, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Verena I GaidzikKonstanze Döhner
Apr 12, 2012·Blood·Ana Flávia Tibúrcio RibeiroRuud Delwel
Jul 4, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jason H MendlerClara D Bloomfield
Jul 24, 2012·Cell·John S WelchRichard K Wilson
Aug 18, 2012·Nature Reviews. Cancer·Alan H ShihRoss L Levine
Aug 25, 2012·Human Pathology·Dinesh RakhejaWeina Chen

❮ Previous
Next ❯

Citations

Nov 17, 2020·Frontiers in Genetics·Ying QuHong Zhou

❮ Previous
Next ❯

Methods Mentioned

BETA
exome sequencing
chip

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.